Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up

INTRODUCTION: Alemtuzumab is highly effective in the treatment of patients with relapsing multiple sclerosis (PwRMS) and selectively targets the CD52 antigen, with a consequent profound lymphopenia, particularly of CD4+ T lymphocytes. However, the immunological basis of its long-term efficacy has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolla, Simona, De Mercanti, Stefania Federica, Bardina, Valentina, Maglione, Alessandro, Taverna, Daniela, Novelli, Francesco, Cocco, Eleonora, Vladic, Anton, Habek, Mario, Adamec, Ivan, Annovazzi, Pietro Osvaldo Luigi, Horakova, Dana, Clerico, Marinella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919044/
https://www.ncbi.nlm.nih.gov/pubmed/35296069
http://dx.doi.org/10.3389/fimmu.2022.818325

Ejemplares similares

Ejemplares similares